Fuzeon Needle-Free Delivery System To Be Resubmitted To FDA In Second Half 2006
Growth for Roche/Trimeris' HIV fusion inhibitor is expected to be driven by the new system, which is currently "approvable" at FDA, and updated HHS treatment guidelines.
Growth for Roche/Trimeris' HIV fusion inhibitor is expected to be driven by the new system, which is currently "approvable" at FDA, and updated HHS treatment guidelines.